Acumen Research and Consulting Ophthalmic Drugs Market | Page 4

diabetic retinopathy by the FDA for its product, Lucentis, to improve its product portfolio. In addition to improving their profitability and gaining a competitive edge on other players, the key players on the Ophthalmic Drugs market employ new ideas and concepts, improve production processes and improve the existing set of products. The key players therefore have taken product development as their key development strategy to be consistent with end users demands. Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press- releases TABLE OF CONTENT CHAPTER 1. INDUSTRY OVERVIEW 1.1. Definition and Scope 1.1.1. Definition of Ophthalmic Drugs 1.1.2. Market Segmentation 1.1.3. List of Abbreviations 1.2. Summary 1.2.1. Market Snapshot 1.2.2. Ophthalmic Drugs Market By Drug Class Outlook 1.2.2.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Drug Class Outlook (2015-2026) 1.2.2.2. Global Ophthalmic Drugs Market Revenue Share By Drug Class Outlook in 2017 1.2.2.3. Antiallergy 1.2.2.4. Anti-Vascular Endothelial Growth Factor (Anti-Vegf) Agents 1.2.2.5. Anti-inflammatory 1.2.2.5.1. Nonsteroidal Drugs 1.2.2.5.2. Steroidal Drugs 1.2.2.6. Antiglaucoma Would like to place an order or any question, please feel free to contact at [email protected] | [phone]